A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Resmetirom for the Treatment of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in People Living with Human Immunodeficiency Virus (HIV)
Summary
The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and HIV. This is a research study to test a drug that is already on the market with a population that was not included in the original clinical trials. Participants will be people over age 18 with HIV who are on antiretroviral therapy and have been diagnosed with MASLD.